Pfizer reported that its obesity drug berobenatide achieved a 15.9% weight loss in a Phase 2b study without placebo adjustment. The pivotal Phase 3 trial for berobenatide is now open for enrollment, aiming to strengthen Pfizer's position in obesity treatment. In 2026, Pfizer plans to conduct 10 Phase 3 studies targeting chronic weight management and obesity-related conditions like knee osteoarthritis and sleep apnea. Additionally, the FDA expanded the indication for Pfizer's HYMPAVZI to include more hemophilia patients, highlighting ongoing advancements in Pfizer's drug portfolio.
Pfizer remains an undervalued stock that has underperformed the market but increased 2% since the last analysis. It is viewed as a defensive holding that provides income and helps offset risks related to AI in a diversified portfolio. Despite recent ...
Pfizer is currently undervalued, trading at just over 8 times its projected 2026 earnings and offering a 7% dividend yield. Its core business, excluding COVID-related drugs, grew 7% in Q1, while new products, especially from its acquisition of Seagen...
